|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
MMP-9 Antibody Datasheet
|Order or Inquire for MMP-9 Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.0195 ng/well in ELISA|
MMP-9 Antibody Product Information
Recombinant Rat MMP-9 protein (Catalog#80049-R08H)
|Antibody Type :||Mouse Monoclonal Antibody ( Mouse mAb Service Platform )|
Clone ID :
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Rat MMP-9 (rR MMP-9; Catalog#80049-R08H; EDL96479.1; Met 1-Pro 708). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
MMP-9 Antibody Usage Guide
No cross-reactivity in ELISA with
Human cell lysate (293 cell line)
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Rat MMP9. The detection limit for Rat MMP9 is approximately .0195 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
MMP-9 Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|MMP-9/MMP9||Human||MMP-9/MMP9 Protein, Recombinant||10327-H08H|
|MMP-9/MMP9||Human||MMP-9/MMP9 Protein, Recombinant||10327-HNAH|
|MMP-9/MMP9||Mouse||MMP-9/MMP9 Protein, Recombinant||50560-MNAH|
|MMP-9/MMP9||Rat||MMP-9/MMP9 Protein, Recombinant||80049-R08H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human MMP-9/MMP9||ELISA||Mouse Monoclonal Antibody||10327-MM01|
|Human MMP-9/MMP9||WB||Mouse Monoclonal Antibody||10327-MM02|
|Human MMP-9/MMP9||ELISA||Rabbit Monoclonal Antibody||10327-RM04|
|Human MMP-9/MMP9||WB, ELISA||Rabbit Monoclonal Antibody||10327-RM05|
|Human MMP-9/MMP9||WB, ELISA||MMP-9/MMP9 Antibody, Rabbit PMb (Biotin conjugated)||10327-R043B|
|Human MMP-9/MMP9||WB, ELISA||Rabbit Polyclonal Antibody||10327-RP03|
|Human MMP-9/MMP9||WB, ELISA||Rabbit Polyclonal Antibody (Antigen Affinity Purified)||10327-RP06|
|Rat MMP-9/MMP9||WB, ELISA||Rabbit Polyclonal Antibody (Antigen Affinity Purified)||80049-RP02|
|Rat MMP-9/MMP9||WB, ELISA||MMP-9 Antibody||80049-MM04|
|Rat MMP-9/MMP9||WB, ELISA||MMP-9 Antibody||80049-MM05|
MMP-9 Antibody Background
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that degrade components of the extracellular matrix (ECM) and play essential roles in various physiological processes such as morphogenesis, differentiation, angiogenesis and tissue remodeling, as well as pathological processes including inflammation, arthritis, cardiovascular diseases, pulmonary diseases and tumor invasion. MMPs are synthesized as enzymogen and converted to active form by other MMPs or extracellular proteinases. MMP-9/MMP9, also known as 92-kDa gelatinase B/type IV collagenase, is secreted from neutrophils, macrophages, and a number of transformed cells, and is the most complex family member in terms of domain structure and regulation of its activity. It contains a fibronectin-like domain, which functions in the binding of gelatin, a unique serine/proline/threonine-rich collagen type V-like domain probably serving as attachment sites of multiple O-linked oligosaccharides and a carboxyl terminal hemopexin-like domain. This enzyme degrades various substrates including gelatin, collagen types IV and V, and elastin. Studies have shown that MMP-9/MMP9 play control roles in IL8-induced leukocytosis and stem cell mobilization, and additionally in release of biologically active VEGF and consequently in the formation of ascites. MMP-9/MMP9 is involved in a variety of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, and be regarded as a potential therapeutic target.
- Ogata, Y. et al., 1992, J. Biol. Chem. 267: 3581-3584.
- Opdenakker, G. et al., 2001, J. Leuko. Biol. 69: 851-859.
- Belotti, D. et al., 2003, Cancer. Res. 63: 5224-5229.
- Mira, E. et al., 2004, J. Cell. Sci. 117: 1847-1857.
- Ram, M. et al., 2006, J. Clin. Immunol. 26: 299-307.
MMP-9 related areas, pathways, and other information